DB-1311

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameDB-1311
Drug Alias NameDB-1311BNT-324
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > P1021 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD276DNA topoisomerase I inhibitors
TargetsCD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDuality Biologics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDuality Biologics (Suzhou) Co LtdBiaoentai (Shanghai) Pharmaceutical Co LtdBiontech Se
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A